Complete Genomics Well Positioned To Move From Research To Clinical In Genome Sequencing

Rod Raynovich submits:The IPO market is setting up for continued investor interest in the biotech sector.

By Medhanie:We knew the likelihood of Complete Genomics (GNOM) remaining an independent company was low. Given its low trading price, difficulty in gaining access to capital and its pending lawsuit with Illumina (ILMN), a sale almost seems inevitable.

By pretty much any measure, biotechnology company Illumina's growth has been spectacular. When Jay Flatley joined as CEO in 1999, the San Diego-based business had 25 people. It now employs more than 3000. The stock price has tripled since its IPO in 2001 to reach new highs this year, and sales hit $1.2 billion in 2012. 

By Tim Gallagher:A trailblazing pioneer, Affymetrix (AFFY) got off largely under-the-radar in 1992, and came public with its IPO in June 1996.

The Burrill Report submits: By Marie DaghlianDNA sequencing firm Complete Genomics (GNOM) went public after scaling back its deal price more than 30 percent to get it done. Shares began trading on the Nasdaq Global Market on Thursday under the symbol GNOM. The stock closed at $8.03, down more than 10 percent on the first day of trading with volume of nearly 2.5 million shares.

The Burrill Report submits: The cost of sequencing a human genome has fallen below $10,000 for the first time, a feat which has the potential to transform research costs and, eventually, therapeutic strategies.

By OneMedPlace: By Herina Ayot Keating Capital’s President Timothy Keating was interviewed by OneMedRadio where he describes the liquidity premium that gives public companies 3x valuation over private company peers and the dramatic decline in IPOs and increase in size that is debilitating economic growth.Click to hear audio and see below for a full transcript.